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 Metabolic dysfunction of adipose tissue due to oxidative 
stress is considered the cause of several complications of 
obesity, such as diabetes and cardiovascular disease ( 1–3 ). 
Dysfunctional adipocytes are associated with the develop-
ment of insulin resistance, hyperglycemia, atherogenic 
dyslipidemia, and arterial hypertension, and they favor a 
prothrombotic and proinfl ammatory state ( 4, 5 ). Oxida-
tive stress in adipose tissue regulates adipogenic response 
with adipocyte hypertrophy ( 6, 7 ). Adipocyte dysfunction 
is caused by a variety of stimuli, including heavy metals, 
reactive oxygen species (ROS), nitric oxide (NO) , Ang II, 
and cytokines. The localized infl ammation with increased 
macrophage infi ltration in adipose tissue leads to impor-
tant changes in adipocyte gene expression, with down-
stream effects on adipocyte lipid metabolism and altered 
endocrine function ( 7 ). Adipocyte differentiation (adipo-
genesis) is a complex process that includes coordinated 
changes in hormone sensitivity and gene expression in re-
sponse to various stimuli, including lipid mediators ( 8 ). 
 20-Hydroxyeicosatetraenoic acid (20-HETE), a product 
of the cytochrome P450 (CYP)-catalyzed   -hydroxylation 
of arachidonic acid, is a primary eicosanoid in the micro-
circulation that plays a role in the regulation of vascular 
tone and renal tubular homeostasis ( 9–12 ). Perturbations 
in the levels of 20-HETE in tissues and biological fl uids 
have been observed in multiple pathological states, includ-
ing hypertension, kidney disease, and metabolic syndrome 
( 13–17 ). 20-HETE stimulates production of superoxide 
and infl ammatory cytokines, inhibits endothelial nitric ox-
ide synthase (eNOS) , and increases oxidative stress ( 18–20 ), 
suggesting a possible role for 20-HETE in the regulation of 
adipogenesis ( 21 ). 
 Abstract  20-Hydroxy-5,8,11,14-eicosatetraenoic acid (20-
HETE), a product of the cytochrome P450 (CYP)-catalyzed 
  -hydroxylation of arachidonic acid, induces oxidative 
stress and, in clinical studies, is associated with increased 
body mass index (BMI) and the metabolic syndrome. This 
study was designed to examine the effects of exogenous 20-
HETE on mesenchymal stem cell (MSC)-derived adipocytes. 
The expression levels of CYP4A11 and CYP4F2 (major 20-
HETE synthases in humans) in MSCs decreased during adi-
pocyte differentiation; however, exogenous administration 
of 20-HETE (0.1–1   M) increased adipogenesis in a dose-
dependent manner in these cells ( P < 0.05). The inability of 
a 20-HETE analog to reproduce these effects suggested the 
involvement of a metabolic product of 20-HETE in mediat-
ing its pro-adipogenic effects. A cyclooxygenase (COX)-1 
selective inhibitor enhanced, whereas a COX-2 selective or a 
dual COX-1/2 inhibitor attenuated adipogenesis induced by 
20-HETE. The COX-derived metabolite of 20-HETE, 20-
OH-PGE 2 , enhanced adipogenesis and lipid accumulation 
in MSCs. The pro-adipogenic effects of 20-HETE and 20-
OH-PGE 2 resulted in the increased expression of the adi-
pogenic regulators PPAR  and   -catenin in MSC-derived 
adipocytes.  Taken together we show for the fi rst time that 
20-HETE-derived COX-2-dependent 20-OH-PGE 2 enhances 
mature infl amed adipocyte hypertrophy in MSC undergoing 
adipogenic differentiation. — Kim, D. H., N. Puri, K. Sodhi, 
J. R. Falck, N. G. Abraham, J. Shapiro, and M. L. Schwartzman. 
 Cyclooxygenase-2 dependent metabolism of 20-HETE in-
creases adiposity and adipocyte enlargement in mesenchy-
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week at concentrations of 0.1 and 1   M. Inhibitors of COX-1 
and COX-2 were added three times a week at a dose of 100 and 
5   M, respectively. 
 Oil Red O staining 
 At day 14 of adipogenesis, 0.21% Oil Red O in 100% isopropa-
nol (Sigma-Aldrich, St. Louis, MO) was used. Briefl y, adipocytes 
were fi xed in 10% formaldehyde, washed in Oil Red O for 10 min, 
rinsed with 60% isopropanol (Sigma-Aldrich). Then the Oil Red 
O was eluted by adding 100% isopropanol for 10 min, and OD 
was measured at 490 nm for 0.5 s reading. MSC-derived adipo-
cytes were measured by Oil Red O staining (OD = 490 nm) after 
day 14. Each value of Oil Red O staining was normalized by the 
cell number. 
 Adipocyte size 
 Lipid droplets were measured using an ImagePro Analyzer 
(Media Cybernetics Corporation, Silver Springs, MD). The MSC-
derived adipocytes were treated with increasing concentration of 
20-OH-PGE2 (1–1,000 nM) every alternate day for 14 days. To 
quantify the number and size of the lipid droplets in these im-
ages, a proprietary algorithm (patent pending) was developed 
that segments circular staining patterns. The algorithm was then 
applied to images obtained from the lipid optical channel for 
cells exposed to different doses of 20-OH-PGE2. 
 mRNA isolation and real-time PCR quantifi cation 
 Total RNA was isolated using the RNeasy mini kit (Qiagen, 
Valencia, CA) according to the manufacturer’s instructions. First-
strand cDNA was synthesized with Roche reverse transcription 
reagents. Total RNA (0.5–1   g) was analyzed by real-time PCR. 
The quantitative real-time polymerase chain reaction (qRT-PCR) 
was performed with the TaqMan gene expression assay on an 
Applied Biosystems 7500 fast real-time PCR system according to 
the manufacturer’s recommended protocol (Applied Biosystems, 
Foster City, CA). Each reaction was run in triplicate. The com-
parative threshold cycle (CT) method was used to calculate the 
amplifi cation fold as specifi ed by the manufacturer. 
 Western blot analysis 
 Western blot analysis of adipocyte cell lysate was carried out as 
described previously ( 6, 26 ). Briefl y, cells were placed in a homog-
enization buffer, and homogenates were centrifuged at 27,000  g 
for 10 min at 4°C. The supernatant was used for the measurement 
of COX-1, COX-2, PPAR  , Mest, and   -catenin protein levels 
( 27, 28 ). The levels were quantifi ed by scanning densitometry using 
an imaging densitometer, normalized to the levels of total protein. 
 PGE 2 measurement 
 PGE 2 levels were determined in the culture supernatant. Mul-
tiple assays were conducted for quantifi cation of the proteins 
(AssayGate Inc., Ijamsville, MD). All measurements were performed 
in triplicate. 
 Statistical analyses 
 Statistical signifi cance between experimental groups was 
determined by the Fisher method of analysis of multiple com-
parisons ( P  < 0.05 was regarded as signifi cant). For comparison 
between treatment groups, the null hypothesis was tested by ei-
ther a single-factor ANOVA for multiple groups or the unpaired 
 t -test for two groups. Data are presented as mean ± SEM. Differ-
ences between experimental groups were evaluated with ANOVA 
with Bonferroni corrections. Statistical signifi cance was regarded 
as signifi cant at  P < 0.05. 
 Prostaglandins (PG) are known to play a variety of roles 
in adipocytes and precursor cells that utilize the arachido-
nate cyclooxygenase (COX) pathway to generate PGs at dif-
ferent stages of the life cycle of adipocytes ( 8 ). COX consists 
of two isozymes, COX-1 and COX-2, and is the rate-limiting 
enzyme that catalyzes the conversion of arachidonic acid 
into PGs by specifi c PG synthases ( 22 ). COX-1 is constitu-
tively expressed in most cells, including adipocytes, whereas 
COX-2 is induced in response to various stimuli, such as 
cytokines and oxidative stress ( 23 ). COX-2 expression is 
transiently enhanced in the early phase of adipogenesis. 
Prostaglandin E2 (PGE 2 ) and prostaglandin F2a (PGF 2   ) 
are anti-adipogenic factors that suppress the differentiation 
of adipocytes ( 23 ). Arachidonic acid metabolism during 
adipogenesis is a process governed at multiple levels, sug-
gesting a complex role for PGs during fat cell development 
( 24 ). The relative contribution of COX-1 and COX-2 to the 
regulation of adipogenesis remains to be resolved. 
 20-HETE plays an important role in inducing oxidative 
stress ( 21 ), and as such, we hypothesize that 20-HETE 
affects adipogenesis. We examined adipogenesis in mesen-
chymal stem cells (MSC), multipotent stromal cells that can 
be induced to differentiate into adipocytes ( 25 ). 20-HETE 
is also a substrate for COX metabolites ; hence, the goal 
of the present study was to evaluate the contribution of 
20-HETE and its COX-derived metabolites to the regula-
tion of adipogenesis. The results of this study suggest that 
COX-derived 20-HETE metabolites are a potential thera-
peutic target in the treatment of obesity and its associated 
disease states: hypertension, the metabolic syndrome, and 
diabetes. 
 MATERIALS AND METHODS 
 Human bone marrow-derived MSC differentiation 
into adipocytes 
 Frozen bone marrow mononuclear cells were purchased from 
Allcells (Emeryville, CA). After thawing, mononuclear cells were 
resuspended in an   -minimal essential medium (  -MEM, Invit-
rogen, Carlsbad, CA) supplemented with 10% heat inactivated 
fetal bovine serum (FBS, Invitrogen) and 1% antibiotics and 
antimycotic (Invitrogen). The cells were plated at a density of 
1–5 × 10 6 cells per 100 cm 2 dish. The cultures were maintained 
at 37°C in a 5% CO 2 incubator. The medium was changed after 
48 h and every 3–4 days thereafter. When the MSCs were confl u-
ent, the cells were recovered by the addition of 0.25% trypsin/
EDTA (Invitrogen). MSCs (passage 2–3) were plated in either a 
75 cm 2 fl ask or a 24-well plate and cultured in   -MEM with 20% 
FBS up to a density of 2.0 × 10 4 cells/cm 2 . The medium was re-
placed with adipogenic medium, and the cells were cultured for 
an additional 14 days. The adipogenic media consisted of com-
plete culture medium supplemented with DMEM-high glucose, 
10% (v/v) FBS, 10 µg/ml insulin, 0.5 mM dexamethasone 
(Sigma-Aldrich, St. Louis, MO), and 1% antibiotics and antimycotic 
(Invitrogen) in the presence and absence of the COX-1 inhibi-
tor (2-valeryloxybenzoic acid, Cayman, Ann Arbor, MI) and 
the COX-2 inhibitor (3-(4-methylsulpho nylphenyl)-4-phenyl-5-
trifl uoromethylisoxazol, Cayman) with and without 20-HETE, 
20-HETE agonist (20-5,14-HEDE), or 20-OH-PGE 2 . 20-HETE, 
20-HETE agonist, or 20-OH-PGE 2 were added three times a 
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20-HETE on lipid accumulation in MSCs derived adipo-
cytes was further refuted by the inability of a 20-HETE ago-
nist [sodium 2-((5Z,14Z)-20-hydroxyicosa-5,14-dienamido)
acetate, 20-HEDE] to mimic the effects of exogenous 
20-HETE as shown in  Fig. 3 .  Results show that in presence 
of COX-1 and COX-2 inhibitors, the 20-HETE agonist 
20-HEDE had no signifi cant effect on adipogenesis, thus 
further substantiating the notion that a COX-2-derived 
metabolic product has an enhanced adipogenic effect. 
Subsequently, addition of the microsomal PGE2 synthase 
inhibitor CAY10526 abolished the adipogenic effect of 
20-HETE in the presence of a COX-1 inhibitor ( Fig. 4 ). 
 Arachidonic acid, which can also be metabolized consec-
utively by CYP and COX enzymes to a similar product, was 
less potent than 20-HETE; it had no effect at 0.1 and 1 µM, 
and at 10 µM, it increased lipid accumulation by 20% (data 
not shown). 
 Effect of 20-hydroxy-PGE 2 on adipogenesis and 
adipocyte hypertrophy 
 Previous studies have shown that 20-HETE is metabo-
lized by COX to 20-OH-endoperoxides and consequently 
to 20-OH-PGE 2 ( 29, 30 ). Therefore, we examined the 
effects of 20-OH-PGE 2 on adipogenesis in the presence 
or absence of COX-1 and COX-2 inhibitors. 20-OH-
PGE 2 stimulated ( P < 0.05) adipogenesis 4-fold as mea-
sured by lipid accumulation ( Fig. 5 ).  Neither COX-1 nor 
COX-2 inhi bitor, alone or together, prevented 20-OH-PGE 2 -
mediated increase in adipogenesis, suggesting a COX-
independent action of this metabolite ( Fig. 5 ). The effect 
of 20-OH-PGE 2 was concentration dependent ( Fig. 6A ).  It 
signifi cantly increased lipid accumulation at 50 nM and had 
maximal effect at 500 nM. Moreover, addition of PGE 2 blun-
ted the adipogenic activity of 20-OH-PGE 2 ; PGE 2 (10 nM) 
inhibited the adipogenic activity of 20-OH-PGE 2 (500 nM) 
by 40% as evidenced by a reduction in lipid accumulation 
measured as absorbance of Oil Red O from 0.38 ± 0.02 to 
0.23 ± 0.02 ( P < 0.05). In addition, 20-OH-PGE 2 stimu-
lated adipocyte hypertrophy as measured by lipid droplet 
size. As seen in  Fig. 6B , lipid droplet size increased 2- and 
3-fold in response to 100 and 1,000 nM of 20-OH-PGE 2 . 
These results strongly suggest that the COX-2 metabolite 
20-hydroxy-PGE 2 plays a signifi cant role in inducing adi-
pogenesis and that its effect may be antagonized by 
PGE 2 . 
 Effect of 20 HETE and 20-OH- PGE 2 on 
adipogenic markers 
 We examined the effects of 20-HETE and 20-OH-PGE 2 
on   -catenin, PPAR  , and Mest expression as adipogenic 
differentiation markers, in the presence and absence of 
COX-1 and COX-2 inhibitors ( Fig. 7 ).  Densitometry analy-
sis showed that the expression of PPAR  and Mest ( Fig. 
7A, B , respectively) was signifi cantly increased in the pres-
ence of 20-OH-PGE 2 when the cells were treated with 
COX-1 or COX-2 inhibitor or both. In contrast,   -catenin 
expression signifi cantly decreased in the presence of 20-
OH-PGE 2 when the cells were treated with COX-1 or COX-2 
inhibitor or both ( Fig. 7C ). Similar data were obtained 
 RESULTS 
 CYP4-  -hydroxylase and COX expression 
during adipogenesis 
 The expression levels of CYP4-  -hydroxylases were de-
termined in MSC before and after completion of adipo-
genesis as shown in  Fig. 1A , B .  MSC expressed relatively 
high mRNA levels of CYP4A11 and CYP4F2 (the major 
20-HETE producing CYP4-  -hydroxylases in humans) ( 17 ) 
before the start of adipogenic differentiation. In adipo-
cytes derived from MSC, mRNA levels of these hydroxy-
lases were nearly undetectable. To evaluate COX activity 
in MSC exposed to adipogenic environment, PGE 2 levels 
were determined in conditioned media ( Fig. 1C ). COX-1 
and COX-2 inhibitors decreased PGE 2 levels compared 
with levels in the conditioned media without indometha-
cin. Addition of indomethacin, which is a dual COX-1 and 
COX-2 inhibitor, further decreased PGE 2 levels ( Fig. 1C ). 
 Effect of 20-HETE and COX inhibition on adipogenesis 
 The effect of 20-HETE on lipid accumulation in MSC-
derived adipocytes was examined in the presence and the 
absence of either a COX-1 or COX-2 inhibitor. 20-HETE 
enhanced lipid accumulation in cells exposed to a COX-1 
inhibitor but not in cells exposed to COX-2 inhibitor ( Fig. 2 ). 
 The absence of such an effect of 20-HETE in cells treated 
with a COX-2 inhibitor alludes to the role of COX-2-
derived 20-HETE metabolic product in mediating these 
enhanced lipogenic effects ( Fig. 2 ). The direct effect of 
 Fig.  1. Levels of mRNA for (A) Cyp4F11 and (B) Cyp4F2 and (C) 
levels of PGE 2 in MSC before and after adipogenic differentiation 
(adipocytes). Data are expressed as means ± SE. * P < 0.05 versus 
MSC,  # P < 0.05 versus vehicle,  + P < 0.05 versus COX-1 or COX-2 
inhibitor. 
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wall and hemopoeitic cells ( 29–31 ). 20-HETE has been 
shown to contribute to the regulation of vascular tone and 
control of blood pressure. Interestingly, along with its po-
tent vasoconstrictor capacity, 20-HETE has been shown to 
mediate cellular proliferation ( 32, 33 ), angiogenesis ( 34, 
35 ), oxidative stress ( 19 ), and infl ammation ( 18 ), all of 
which may contribute importantly to the process of adipo-
genesis. Metabolic imbalance, frequently accompanying 
pathophysiological conditions traditionally associated with 
enhanced 20-HETE synthesis, was the focus of this study. 
The   -Hydroxylase expression declined in hMSCs as they 
differentiated into adipocytes, thus limiting their autocrine 
exposure to endogenously generated 20-HETE. This may 
be a consequence of in vitro cell culturing conditions. The 
ability of adipose tissue to produce 20-HETE needs to be 
further assessed. Nevertheless, this does not preclude non-
adipocyte sources of this eicosanoid, including 20-HETE 
from the vascular smooth muscle cells of the arteries vas-
cularizing the adipose tissues ( 10, 11, 13, 14 ) as well as 
20-HETE from circulating blood cells ( 36, 37 ). We showed 
a dose-dependent adipogenic response to 20-HETE in hM-
SCs, which was characterized by increased adipocyte 
hypertrophy and increased lipid accumulation. These 
fi ndings highlight a potential role for 20-HETE in promot-
ing lipid accumulation, which in turn has been strongly 
linked to adipocyte dysfunction and disruption of energy 
balance. 
 The inability of a 20-HETE analog to reproduce the en-
hanced adipogenic effects of 20-HETE led us to examine 
the hypothesis that a catabolic product of 20-HETE may 
be responsible for mediating these effects. 20-HETE is a 
known substrate for COX-2 with the resultant formation 
of 20-OH-PGG 2 ( 30 ). Human MSCs have an abundance 
of microsomal PGE synthase (mPGES-1), the product of 
which, PGE 2 , is an inhibitor of adipogenesis ( 38 ). Findings 
in this study suggested that a COX-2-dependent 20-HETE 
metabolite, most probably 20-OH-PGE 2 , appears to medi-
ate the adipogenic effect of 20-HETE on hMSCs-derived 
adipocytes. Blockade of the adipogenic effects of 20-HETE 
by a selective inhibitor of COX-2 or a specifi c mPGES-1 
inhibitor supports this theory. In addition, administration 
of 20-OH-PGE 2 had a similar effect on hMSCs to that ob-
served during 20-HETE treatment. 20-OH-PGE 2 could also 
be synthesized by the sequential metabolism of arachi-
donic acid by COX and   -hydroxylases; however, this 
seems unlikely due to the nearly absent expression of   -
hydroxylases in maturing adipocytes. 
 Our hypothesis that the metabolic product of 20-HETE, 
most likely 20-OH-PGE 2 , is primarily a derivative of COX-2 
stems from the observation that 20-HETE has no measur-
able effects on lipid accumulation on adipocytes undergo-
ing COX-2 blockade, either alone or in combination with 
COX-1 blockade. Absence of a stimulatory effect of 20-HETE 
on hMSC-derived adipocytes in the absence of any COX 
blockade indicates the reciprocal effects of arachidonic acid-
derived PGE 2 and 20-HETE-derived 20-OH-PGE 2 . PGE 2 in-
hibits adipogenesis, and for this reason, in vitro analysis of 
adipogenesis is traditionally carried out in a setting of COX 
blockade. We propose that the COX-2-derived metabolic 
with 20-HETE, except that in the presence of a COX-2 in-
hibitor, the effect was blunted (data not shown). 
 DISCUSSION 
 In the present study, we demonstrated the stimulatory 
effect of exogenous 20-HETE on lipid accumulation in 
MSC-derived adipocytes. 20-HETE, a metabolic product 
of   -hydroxylases, is produced in physiologically relevant 
amounts by various tissues and cells, including the vascular 
 Fig.  2. Effect of 20-HETE on adipogenesis in the presence and 
absence of indomethacin, COX-1 inhibitor (valeroyl salicylate), 
and COX-2 inhibitor (CAY10404). Adipogenesis was measured as 
the relative absorbance of Oil Red O at day 14 after inducing adi-
pogenesis as described in Materials and Methods. Mean ± SE, * P < 
0.05 versus vehicle. 
 Fig.  3. Effect of a 20-HETE agonist on adipogenesis in the pres-
ence and absence of COX-1 or COX-2 inhibitor. Adipogenesis was 
measured as the relative absorbance of Oil Red O at day 14 after 
inducing adipogenesis as described in Materials and Methods. 
Mean ± SE. 
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showed a signifi cant correlation between 20-HETE levels 
and BMI, as well as with oxidative stress and endothelial 
dysfunction in hypertensive individuals ( 43–46 ). A recent 
study in our laboratory examined associations between cir-
culating 20-HETE levels and the function of endothelial 
progenitor cells in diabetic and nondiabetic patients under-
going cardiac bypass surgery. This study found that levels 
of 20-HETE are signifi cantly elevated in diabetic patients 
and that 20-HETE correlated with BMI in both diabetic 
product of 20-HETE counteracts the anti-adipogenic effects 
of PGE 2 . The source of PGE 2 appears to be predominantly 
COX-1, as the basal level of adipogenesis is far greater in 
the presence of a COX-1 inhibitor than in the presence of 
a COX-2 inhibitor. The combination treatment of hMSCs 
with COX-1 and COX-2 inhibitors does not lead to increased 
adipogenesis compared with cells undergoing COX-1 block-
ade alone, further strengthening the notion that the in-
hibitory eicosanoid PGE 2 is principally a catabolic product 
of COX-1. 
 Our proposal of the occurrence of reciprocal effects of 
PGE 2 and 20-OH PGE 2 on adipogenesis in hMSCs is 
strengthened by the demonstrations of a rightward shift 
of the dose-dependent adipogenic response in cells con-
currently exposed to low concentrations of exogenous 
PGE 2 . The adipogenic activity of 20-HETE and 20-OH-PGE2 
was associated with a marked increase in the expression 
of two major pro-adipogenic factors, PPAR  and Mest, 
and a decrease in   -catenin, which is a key anti-adipogenic 
regulator ( 39 ). 20-HETE and its metabolites were impli-
cated as PPAR  activators ( 40, 41 ). In addition to increas-
ing lipid accumulation, 20-HETE also enhanced hMSC 
COX-2 expression, which could provide a microenviron-
ment more conducive to the formation of 20-OH-PGE 2 . It 
is possible that 20-HETE and/or 20-OH-PGE2 stimulate 
transcription activation of the PPAR  receptor and 
thereby set in motion a pro-adipogenic program that is 
further evidenced by increasing the expression of Mest 
and suppressing   -catenin. Additional studies are needed 
to fully identify the precise mechanisms of action of this 
eicosanoid. 
 20-HETE has been shown to increase in experimental 
models of diabetes and obesity ( 42 ). The clinical relevance 
of 20-HETE as a pro-adipogenic agent has been suggested 
in several studies. A report by Laffer et al. ( 15 ) showed a cor-
relation between levels of 20-HETE and circulating insulin 
in essential hypertension with obesity. Croft and colleagues 
 Fig.  4. Effect of 20-HETE on adipogenesis in the 
presence and absence of COX-1 inhibitor, COX-2 in-
hibitor, and the PGE2 synthase inhibitor (CAY10526). 
Adipogenesis was measured as the relative absor-
bance of Oil Red O at day 14 after inducing adipo-
genesis as described in Materials and Methods. Mean ± 
SE, * P < 0.05 versus vehicle,  # P < 0.05 versus control . 
 Fig.  5. Effect of 20-OH-PGE 2 on adipogenesis in the presence and 
absence of COX-1 inhibitor and/or COX-2 inhibitor. Adipogenesis 
was measured as the relative absorbance of Oil Red O at day 14 after 
inducing adipogenesis as described in Materials and Methods. Mean 
± SE, * P < 0.05 versus vehicle,  # P < 0.05 versus control. 
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20-OH-PGE2 could serve as an antagonist to the PGE 2 -
dependent anti-adipogenic effects and contribute toward 
adipocyte hypertrophy and dysfunctional adipogenesis 
frequently associated with pathophysiological conditions, 
such as the metabolic syndrome. A selective COX-2 in-
hibitor could ablate these effects and could, in part, be 
used therapeutically in the fi ght against these chronic 
pathological conditions.  
and nondiabetic patients ( 47 ). Taken together, these 
studies and the current fi ndings suggest that 20-HETE 
may play an important role in the regulation of adipose 
tissue. 
 In conclusion, we characterize a pro-adipogenic role 
of 20-HETE in adipocytes that appears to be mediated by 
a COX-2-dependent catabolic product. Additional analysis 
suggested that the mediator in question is 20-OH-PGE 2 . 
 Fig.  6. (A) Concentration-dependent effect of 20-OH-PGE 2 on adipogenesis. Mean ± SE, * P < 0.05 versus 
1 nM concentration of 20-OH-PGE 2 . (B) Effect of 20-OH-PGE2 on adipocyte size. Mean ± SE, * P < 0.05, and 
** P < 0.01 versus control. 
 Fig.  7. Effect of 20-OH-PGE 2 on adipogenic mark-
ers. Expression of (A) PPAR  , (B) Mest, and (C)   -
catenin was determined by Western blot analysis in 
MSC-derived adipocytes. Quantitative densitometry 
evaluation of the proteins ratio was determined. Data 
are expressed as means ± SE, * P < 0.05 versus corre-
sponding conditions without 20-OH-PGE 2 . 
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